azd5672

AZD5672 is an orally active, potent, and selective small molecule antagonist of the chemokine receptor CCR5. It was developed by AstraZeneca as a potential treatment for rheumatoid arthritis and has also been studied in pharmacokinetic and drug interaction studies. The drug acts by blocking CCR5, a receptor involved in immune cell trafficking and inflammation; high levels of CCR5 are associated with rheumatoid arthritis. Despite promising preclinical activity, clinical trials failed to demonstrate efficacy in rheumatoid arthritis patients, leading to discontinuation of its development for this indication[1][4][6].

Other names

780750-65-4UNII-61XQN688TWUNII61XQN688TWUNII 61XQN688TWCHEMBL212689CHEMBL-212689CHEMBL 212689(R)-N-(1-(3-(3,5-difluorophenyl)-3-(4-(methylsulfonyl)phenyl)propyl)piperidin-4-yl)-N-ethyl-2-(4-(methylsulfonyl)phenyl)acetamide